Advanced Therapy Medicinal Products (ATMPs) are at the frontier of new medicine. The revolution is in the nature of these drugs and in their groundbreaking new opportunities for the treatment of disease. The manufacture involves a new generation of bioreactors, both modular and single-use for dedicated batches and appropriate for the treatment of a single patient. Together with the incredible opportunities of ATMPs, there are challenges that must be addressed such as their cost-benefit, sustainability by national health systems and access to a greater number of patients.
EIPG inviterer til webinar den 3.oktober kl 17:00 (CEST)
Påmeldingslinke finner du under.
Learning Outcomes at the end of this webinar you will be able to:
− Define the current revolution in medicine and understand the definition and description of ATMPs
− Compare the differences between synthetic small molecules and monoclonal antibiodies
− Outline the development process of an ATMP, be aware of the case histories of ATMPs on the market (CART Kymriah, Yescarta, Genic Therapy Luxturna), understand the revolution of ATMPs manufacturing and their future manufacture
− Be informed about the regulations driving the steps in the development of ATMPs
− Recognise the concept of sustainability of these drugs by the NHS and the concept of access to patients
− Appreciate the evolution of ATMPs is in curing not only haematological diseases but also solid tumours.
To Join the Webinar Please register by filling out the Registration Form. Keep a record of the streaming details of the event that will be shown on your screen at the time of your registration. Continuing Education A certificate of attendance will be issued after the webinar. The session will be an hour of Continuing Education